Trial Profile
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Gancotamab (Primary) ; Cyclophosphamide; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- Sponsors Merrimack Pharmaceuticals
- 26 Oct 2018 Status changed from active, no longer recruiting to completed, according to the results published in the British Journal of Cancer
- 26 Oct 2018 Results published in the British Journal of Cancer
- 15 Mar 2017 Results of enhanced permability and retention using 64Cu-labeled nanoparticle (64Cu-MM-302; n=19) published in the Clinical cancer research: an official journal of the American Association for Cancer Research